Galapagos terminates R&D collaboration with Ryvu

Noting that sometimes such collaborations will lead to success and result in approved drugs, but in many cases, they will be terminated for scientific or business reasons, Poland’s oncology specialist Ryvu Therapeutics (WSE: RVU) late Thursday announced that its accord with Belgium’s Galapagos (Euronext: GLPG) in inflammatory disorders entered into in April 2020 had been terminated.

As a result of the termination of the agreement, after the expiration of the notice period, which will last for 30 days, the granted license will expire, and Ryvu will obtain full ownership rights to all molecules and related know-how transferred to Galapagos on the basis of the agreement and generated within the scope of the deal prior to Galapagos exercising the option. Ryvu is also entitled to obtain an exclusive royalty-bearing license to the intellectual property generated by Galapagos, after the exercise of the option to continue the program development.

Terms do not require repayments